BRIEF-Pepgen Inc - U.S. FDA Places FREEDOM2 Trial On Partial Clinical Hold Related To Preclinical Pharmacology And Toxicology

Reuters03-05

March 4 (Reuters) - PepGen Inc PEPG.O:

PEPGEN INC: U.S. FDA PLACES FREEDOM2 TRIAL ON PARTIAL CLINICAL HOLD RELATED TO PRECLINICAL PHARMACOLOGY AND TOXICOLOGY
PEPGEN INC: REITERATES GUIDANCE FOR REPORTING DATA FROM FREEDOM2 5 MG/KG COHORT IN Q1 2026 AND FROM 10 MG/KG COHORT IN 2H 2026
PEPGEN INC - RECEIVES REGULATORY CLEARANCE TO INITIATE FREEDOM2 IN SOUTH KOREA, AUSTRALIA, AND NEW ZEALAND

Source text: ID:nBwbh3kDba

Further company coverage: PEPG.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2617872561?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-05 05:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617872561","market":"fut","top_or_hot":-1,"title":"BRIEF-Pepgen Inc - U.S. FDA Places FREEDOM2 Trial On Partial Clinical Hold Related To Preclinical Pharmacology And Toxicology","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Pepgen Inc - U.S. FDA Places FREEDOM2 Trial On Partial Clinical Hold Related To Preclinical Pharmacology And Toxicology</title></head><body><p><span>March 4 (Reuters)</span><span> - </span>PepGen Inc <span>PEPG.O</span>:</p><ul><li><p>PEPGEN INC: U.S. FDA PLACES FREEDOM2 TRIAL ON PARTIAL CLINICAL HOLD RELATED TO PRECLINICAL PHARMACOLOGY AND TOXICOLOGY</p></li><li><p>PEPGEN INC: REITERATES GUIDANCE FOR REPORTING DATA FROM FREEDOM2 5 MG/KG <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> IN Q1 2026 AND FROM 10 MG/KG COHORT IN 2H 2026</p></li><li><p>PEPGEN INC - RECEIVES REGULATORY CLEARANCE TO INITIATE FREEDOM2 IN SOUTH KOREA, AUSTRALIA, AND NEW ZEALAND</p></li></ul><p>Source text: <span>ID:nBwbh3kDba</span></p><p>Further company coverage: <span>PEPG.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Pepgen Inc - U.S. FDA Places FREEDOM2 Trial On Partial Clinical Hold Related To Preclinical Pharmacology And Toxicology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Pepgen Inc - U.S. FDA Places FREEDOM2 Trial On Partial Clinical Hold Related To Preclinical Pharmacology And Toxicology\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-05 05:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Pepgen Inc - U.S. FDA Places FREEDOM2 Trial On Partial Clinical Hold Related To Preclinical Pharmacology And Toxicology</title></head><body><p><span>March 4 (Reuters)</span><span> - </span>PepGen Inc <span>PEPG.O</span>:</p><ul><li><p>PEPGEN INC: U.S. FDA PLACES FREEDOM2 TRIAL ON PARTIAL CLINICAL HOLD RELATED TO PRECLINICAL PHARMACOLOGY AND TOXICOLOGY</p></li><li><p>PEPGEN INC: REITERATES GUIDANCE FOR REPORTING DATA FROM FREEDOM2 5 MG/KG <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> IN Q1 2026 AND FROM 10 MG/KG COHORT IN 2H 2026</p></li><li><p>PEPGEN INC - RECEIVES REGULATORY CLEARANCE TO INITIATE FREEDOM2 IN SOUTH KOREA, AUSTRALIA, AND NEW ZEALAND</p></li></ul><p>Source text: <span>ID:nBwbh3kDba</span></p><p>Further company coverage: <span>PEPG.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PEPG","symbol_name":"PepGen Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nFWN3ZS1YQ:1","article_id":"2617872561","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617872561","pubTimestamp":1772659697,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Pepgen Inc - U.S. FDA Places FREEDOM2 Trial On Partial Clinical Hold Related To Preclinical Pharmacology And ToxicologyMarch 4 (Reuters) - PepGen Inc PEPG.O:PEPGEN INC: U.S. FDA PLACES FREEDOM2 ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PEPG":"PepGen Inc.","BK4139":"生物科技"},"translate_title":"简介-Pepgen Inc-美国FDA将FREEDOM2试验与临床前药理学和毒理学相关的部分临床搁置","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PEPG":0.9},"content_text":"BRIEF-Pepgen Inc - U.S. FDA Places FREEDOM2 Trial On Partial Clinical Hold Related To Preclinical Pharmacology And ToxicologyMarch 4 (Reuters) - PepGen Inc PEPG.O:PEPGEN INC: U.S. FDA PLACES FREEDOM2 TRIAL ON PARTIAL CLINICAL HOLD RELATED TO PRECLINICAL PHARMACOLOGY AND TOXICOLOGYPEPGEN INC: REITERATES GUIDANCE FOR REPORTING DATA FROM FREEDOM2 5 MG/KG COHORT IN Q1 2026 AND FROM 10 MG/KG COHORT IN 2H 2026PEPGEN INC - RECEIVES REGULATORY CLEARANCE TO INITIATE FREEDOM2 IN SOUTH KOREA, AUSTRALIA, AND NEW ZEALANDSource text: ID:nBwbh3kDbaFurther company coverage: PEPG.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2617872561","isCrawlerRequest":true}